Ethosuximide and Irritable Bowel Syndrome–Related Abdominal Pain

In this randomized clinical trial in 124 patients assessing ethosuximide to improve IBS-related abdominal pain, intention-to-treat analysis showed no significant difference in responder rates between ethosuximide and placebo. Ethosuximide had limited tolerability, with higher discontinuation rates, and induced more adverse events compared with placebo.